HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
HUTCHMED (China) Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$14.18+0.13 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 31, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 28, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 1, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 3, 2022 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Oncology/Immunology consolidated revenue | full year 2026 | $330.00M to $450.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements HUTCHMED (China) filed with the SEC
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
EX-99.1 to Form 6-K
(Incorporated in the Cayman Islands with limited liability)
EX-99.1 to Form 6-K
Announcement pursuant to AIM Rule 17 Schedule 2(g) Update
EX-99.1 to Form 6-K
HUTCHMED Reports 2026 Interim Results
EX-99.1 to Form 6-K
HUTCHMED to Announce 2026 Half-Year Financial Results
EX-99.1 to Form 6-K
Annual General Meeting held on May 1 2 , 202 6 – Poll Results
EX-99.1 to Form 6-K
+44 20 3727 1030 / [email protected]
EX-99.1 to Form 6-K
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
EX-99.1 to Form 6-K
2025 Annual Report and Notice of Annual General
EX-99.2 to Form 6-K
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
EX-99.4 to Form 6-K
Vesting of awards under the Long Term Incentive Plan
EX-99.1 to Form 6-K
Vesting of awards under the Long Term Incentive Plan
EX-99.1 to Form 6-K
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK ® in China
EX-99.1 to Form 6-K
Intended r etirement of Independent Non-executive Director
EX-99.1 to Form 6-K
HUTCHMED Reports 2025 Full Year Results and
EX-99.1 to Form 6-K
Balance Sheets (Parent Company Only)
EX-99.2 to Form 6-K
HUTCHMED to Announce 2025 Final Results
EX-99.1 to Form 6-K
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
EX-99.1 to Form 6-K
+44 20 3727 1030 / [email protected]
EX-99.1 to Form 6-K